Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
J Ocul Pharmacol Ther. 2023 Dec;39(10):675-691. doi: 10.1089/jop.2023.0069. Epub 2023 Aug 23.
Antibody-drug conjugates (ADCs) are a growing class of chemotherapeutic agents for the purpose of treating cancers that often have relapsed or failed first- and second-line treatments. ADCs are composed of extremely potent cytotoxins with a variety of side effects, one of the most significant being ocular toxicity. The available literature describes these toxicities as varying in severity and in incidence, although with disparate methods of evaluation and management. Some of the most common toxicities include microcyst-like epithelial keratopathy and dry eye. We discuss proposed mechanisms of ocular toxicity and describe the reports that mention these toxicities. We focus on ADCs with the most published literature and the most significant effects on ocular tissue. We propose areas for further investigation and possible ideas of future management. We provide a comprehensive look at the reports of ADCs in current literature to better inform clinicians on an expanding drug class.
抗体药物偶联物（ADCs）是一类新兴的化疗药物，用于治疗经常复发或一线和二线治疗失败的癌症。ADCs 由各种具有不同副作用的强效细胞毒素组成，其中最显著的是眼毒性。现有文献描述了这些毒性的严重程度和发生率各不相同，尽管评估和管理方法不同。一些最常见的毒性包括微囊样上皮角膜病变和干眼症。我们讨论了眼部毒性的可能机制，并描述了提到这些毒性的报告。我们专注于具有最多文献报道和对眼部组织有显著影响的 ADC。我们提出了进一步研究的领域和未来管理的可能思路。我们对当前文献中 ADC 的报告进行了全面的考察，以便更好地为临床医生提供一个不断扩展的药物类别信息。
